4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H 3 receptor antagonists

Journal of Medicinal Chemistry

Volumn 50, Issue 26, 2007, Pages 6706-6717

  Procopiou, Panayiotis A ^a   Ancliff, Rachael A ^a   Bamford, Mark J ^a   Browning, Christopher ^a   Connor, Helen ^a   Davies, Susannah ^a   Fogden, Yvonne C ^a   Hodgson, Simon T ^a   Holmes, Duncan S ^a   Looker, Brian E ^a   Morriss, Karen M L ^a   Parr, Christopher A ^a   Pickup, Elizabeth A ^a   Sehmi, Sanjeet S ^a   White, Gemma V ^a   Watts, Clarissa J ^a   Wilson, David M ^a   Woodrow, Michael D ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [(1 CYCLOBUTYL 4 PIPERIDINYL)OXY]PHENYL] 4 [(4 FLUOROPHENYL)CARBONYL] 2 PIPERAZINONE; 4 [(2,4 DIFLUOROPHENYL)CARBONYL] 1 [4 [[3 (2 METHYL 1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 2 PIPERAZINONE FORMATE; 4 [(4 FLUOROPHENYL)CARBONYL] 1 [4 [[3 (1 PIPERIDINYL)PROPYL]OXY]PHENYL] 2 PIPERAZINONE FORMATE; AMINE; BENZENE DERIVATIVE; CYCLOBUTANE DERIVATIVE; CYTOCHROME P450; FLUORINE DERIVATIVE; HISTAMINE H3 RECEPTOR ANTAGONIST; KETONE DERIVATIVE; NITRILE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CEREBRAL CORTEX; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HISTAMINE H3 ANTAGONISTS; HUMANS; ILEUM; ISOENZYMES; ISOMETRIC CONTRACTION; MALE; MUSCLE, SMOOTH; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37349005513     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0708228     Document Type: Article

References (66)

1. Bousquet, J.; Van Cauwnberge, P.; Khaltaev, N. ARIA Workshop Group, World Health Organization. Allergic rhinitis and impact on asthma. J. Allergy Clin. Immunol. 2001, 108 (5, Suppl.), S147-S336.
2. Berger, W. E. Overview of allergic rhinitis. Ann. Allergy Asthma Immunol. 2003, 90, 7-12.
3. Akdis, C. A.; Blaser, K. Histamine in the immune regulation of allergic inflammation. J. Allergy Clin. Immunol. 2003, 112, 15-22.
4. 1-antihistamines: more relevant than ever in the treatment of allergic disorders. J. Allergy Clin. Immunol. 2003, 112 (4), S42-S52.
5. Ganellin, C. R. In Pharmacology of Histamine Receptors; Ganellin, C. R.; Parsons, M. E., Eds.; Wright: Bristol, U.K., 1982; pp 11-102.
6. 3) of histamine receptor. Nature 1983, 302, 832-837.
7. 3 Receptor. A Target for New Drugs, 1st ed.; Leurs, R., Timmerman, H., Eds.; Elsevier: Amsterdam, 1998.
8. 1 receptor agonists and antagonists. Trends Pharmacol. Sci. 1998, 19, 177-183.
9. 4) expressed in bone marrow. Mol. Pharmacol. 2001, 59, 420-426.
10. 3 receptor-mediated inhibition of noradrenaline release in pig retina discs. Arch. Pharmcol. 1987, 324, 497-501.
11. 3 receptor-mediated inhibition of neurogenic vasopressor responses in the pithed rats. Eur. J. Pharmacol. 1991, 205, 307-310.
12. 3-receptors. Br. J. Pharmacol. 1992, 107, 347-350.
13. 3 receptor agonist Sch 50971. Arzneim.-Forsch./Drug Res. 1998, 48, 881-888.
14. 3 receptors. Naunyn-Schmiedeburg's Arch. Pharmacol. 1992, 346, 46-50.
15. 3 receptors in human saphenous vein and guinea pig ileum. Eur. J. Pharmacol. 1999, 366, 73-78.
16. 3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur. J. Pharmacol. 2002, 452, 339-345.
17. 3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur. J. Pharmacol. 2004, 484, 83-89.
18. 3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am. J. Rhinol. 1999, 13, 391-399.
19. 3-receptor antagonist N-(3,5- dichlorophenyl)-N′-[[4-(1H-imidazol-4-ylmethyl)phenyl] -methyl]-urea (Sch 79687). J. Pharmacol. Exp. Ther. 2003, 305, 1037-1044.
20. Taylor-Clark, T.; Sodha, R.; Warner, B.; Foreman, J. Histamine receptors that influence blockage of the normal human nasal airway. Br. J. Pharmacol. 2005, 144, 867-874.
21. 1 antagonist chlorpheniramine. Bioorg. Med. Chem. Lett. 2003, 13, 1959-1961.
22. 3-receptor antagonists. Eur. J. Pharm. Sci. 2001, 13, 249-259.
23. 3 pharmacophores. Bioorg. Med. Chem. Lett. 2007, 17, 5325-5329.
24. 3 antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4799-4803.
25. 3 antagonists and serotonin transporter inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4374-4377.
26. 3 antagonists with serotonin reuptake inhibitor activity. Bioorg. Med. Chem. Lett. 2007, 17, 3130-3135.
27. 3 antagonist and serotonin transporter inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 2603-2607.
28. 3 antagonists and serotonin reuptake transporter inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 2566-2569.
29. 3 antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 1047-1051.
30. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 897-900.
31. 3 antagonists. J. Med. Chem. 2005, 48, 2229-2238.
32. 3 receptor antagonists derived from ligand based design. Bioorg. Med. Chem. Lett. 2007, 17, 3670-3675.
33. 3 antagonist receptor activity. A new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg. Med. Chem. Lett. 2006, 16, 5303-5308.
34. 3 receptor. Bioorg. Med. Chem. Lett. 2006, 16, 3162-3165.
35. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 3415-3418.
36. Berlin, M.; Ting, P. C.; Vaccaro, W. D.; Aslanian, R.; McCormick, K. D.; Lee, J. F.; Albanese, M. M.; Mutahi, M. W.; Piwinski, J. J.; Shih, N-Y.; Duguma, L.; Solomon, D. M.; Zhou, W.; Sher, R.; Favreau, L.; Bryant, M.; Korfmacher, W. A.; Nardo, C.; West, R. E.; Anthes, J. C.; Williams, S. M.; Wu, R.-L.; She, H. S.; Rivelli, M. A.; Corboz, M. R.; Hey, J. A. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)]piperidine series of histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 989-994.
37. Vaccaro, W. D.; Sher, R.; Berlin, M.; Shih, N-Y.; Aslanian, R.; Schwerdt, J. H.; McCormick, K. D.; Piwinski, J. J.; West, R. E.; Anthes, J. C.; Williams, S. M.; Wu, R-L.; She, H. S.; Rivelli, M. A.; Mutter, J. C.; Corboz, M. R.; Hey, J. A.; Favreau, L. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorg. Med. Chem. Lett. 2006, 16, 395-399.
38. 3 receptor antagonists with improved potency. J. Med. Chem. 2005, 48, 6482-6490.
39. Gfesser, G. A.; Faghih, R.; Bennani Youssef, L.; Curtis, M. P.; Esbenshade, T. A.; Hancock, A. A.; Cowart, M. D. Structure - activity relationships of arylbenzofuran H3 receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 2559-2563.
40. 3 receptor antagonists with a rigid biphenyl scaffold. Bioorg. Med. Chem. Lett. 2006, 16, 4063-4067.
41. 3- receptor antagonists of the 2-aminobenzimidazole series. Bioorg. Med. Chem. 2006, 14, 1413-1424.
42. 3 receptor antagonists. Bioorg. Med. Chem. 2006, 14, 3522-3529.
43. Govoni, M.; Lim, H. D.; El-Atmioui, D.; Menge, W. M. P. B.; Timmerman, H.; Bakker, R. A.; Leurs, R.; De Esch, I. J. P. A chemical switch for the modulation of the functional activity of higher homologues of histamine on the human histamine H3 receptor: effect of various substitutions at the primary amino function. J. Med. Chem. 2006, 49, 2549-2557.
44. 3 antagonists. Eur. J. Med. Chem. 2005, 40, 15-23.
45. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1767-1770.
46. 3-receptor antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 3309-3312.
47. 3 receptor ligands with combined inhibitory histamine N-methyltransferase activity. J. Med. Chem. 2002, 45, 1128-1141.
48. Faghih, R.; Dwight, W.; Vasudevan, A.; Dinges, J.; Conner, S. E.; Esbenshade, T. A.; Bennani, Y.-L.; Hancock, A. A. Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. Bioorg. Med. Chem. Lett. 2002, 12, 3077-3079.
49. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1325-1328.
50. 3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. 2004, 14, 689-693.
51. 3 receptor antagonists potently enhance cognition and attention. J. Med. Chem. 2005, 48, 38-55.
52. 3 receptor antagonists. J. Med. Chem. 2005, 48, 306-311.
53. Klapars, A.; Huang, X.; Buchwald, S. L. A general and efficient copper catalyst for the amidation of aryl halides. J. Am. Chem. Soc. 2002, 124, 7421-7428.
54. 2+] using the fluorometric imaging plate reader (FLIPR). Methods Mol. Biol. 1999, 114, 125-133.
55. De Ponti, F.; Poluzzi, E.; Cavalli, A.; Recanatini, M.; Montanaro, N. Safety of nonantiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002, 25, 263-286.
56. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davies, A. M.; Leeson, P. D. A comparison of physicochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256.
57. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
58. 3 antagonists. Inflammation Res. 2004, 53 (Suppl. 1), S69-S70.
59. Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J.-P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16, 1514-1519.
60. 3 receptor antagonists with high CNS penetration. Bioorg. Med. Chem. Lett. 200717, 1443-1446.
61. Ku, Y.-Y.; Cowart, M. D.; Sharma, P. N. Process for Preparing 2-Methylpyrrolidine and Specific Enantiomers Thereof. US2004/ 0171845, 2004.
62. Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M. H.; Reynolds, D. P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm. Sci. 2003, 92, 2236-2248.
63. Cheng, Y. C.; Prusoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
64. Leff, P.; Dougall, I. G. Further concerns over Cheng-Prusoff analysis. Trends Pharmacol. Sci. 1993, 14, 110-112.
65. Rang, H. P. Stimulant actions of volatile anaesthetics on smooth muscle. Br. J. Pharmacol. 1964, 22, 356-365.
66. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.